Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F18%3AN0000068" target="_blank" >RIV/00023728:_____/18:N0000068 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1007/s10067-018-4074-6" target="_blank" >https://doi.org/10.1007/s10067-018-4074-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10067-018-4074-6" target="_blank" >10.1007/s10067-018-4074-6</a>

Result language

angličtina

Original language name

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial

Original language description

GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-na < ve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30226 - Rheumatology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

CLINICAL RHEUMATOLOGY

ISSN

0770-3198

e-ISSN

1434-9949

Volume of the periodical

37

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

4

Pages from-to

1417-1420

UT code for WoS article

000430711600036

EID of the result in the Scopus database

2-s2.0-85044720084